Cardiovascular outcome trials of glucose-lowering therapies.
Kamlesh KhuntiMelanie J DaviesSamuel SeiduPublished in: Expert review of pharmacoeconomics & outcomes research (2020)
Selection of glucose-lowering therapy in the management of T2DM should be individualized and based on patient characteristics, associated comorbidities, patient preference, affordability and adherence to treatment. In view of the benefits seen in the CVOTs with SGLT2 inhibitors and GLP-1 receptor agonists, these newer classes should be the preferred choice in patients with/without established atherosclerotic cardiovascular disease and chronic kidney disease.